This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Study Shows Nanosphere Verisens(TM) CTnI Ultra-Sensitive Troponin I Assay Predicts Heart Failure Deterioration

NORTHBROOK, Ill., Dec. 17, 2010 (GLOBE NEWSWIRE) -- A clinical study released online by the European Journal of Heart Failure, a publication of the European Society of Cardiology, demonstrates the value of using Nanosphere's (Nasdaq:NSPH) Verisens™ cTnI assay (RUO) to detect very low levels of troponin I in hospitalized patients with heart failure.*

The research, conducted at the Veterans Affairs (VA) Hospital in San Diego, was part of the "Veterans Affairs Effects of Therapy" study. In addition to the VA, there were investigators from UCSD and the Cleveland Clinic. The study employing the Verisens™ assay for troponin I involved 144 patients discharged with acute heart failure, who were followed for 90 days. 

Both the BNP and the Verisens™ cTnI assay were tested on blood drawn at admission, discharge, and up to four consecutive days while hospitalized. The new Verisens™ cTnI assay could quantitatively measure troponin I in more than 99% of blood samples. Even at low concentrations, troponin I in the higher quartiles identified increased risk of death and re-hospitalization for patients. Additionally, patients who had rising levels at any concentration while treated in the hospital, had a higher risk of death. Of further note, these results were statistically significant for the Verisens™ cTnI assay, but not for BNP.

"These results are already proving the value of the Nanosphere Verisens™ technology's unmatched sensitivity to measure protein biomarkers, such as low levels of troponin I in heart failure patients," emphasized Winton Gibbons, Senior Vice President of Business Development at Nanosphere.

Additionally, Dr. Alan Maisel, an investigator on the study and well-know expert in biomarkers for heart failure comments that, "We have proven serial sampling of high sensitivity troponin levels in patients admitted for acute heart failure will accomplish two things. First, it will help rule out occlusion of a coronary artery (low levels of troponin) as a cause for decompensation.  Secondly, it will help risk stratify patients.  Eventually this will allow us to use these high-sensitive levels to target with newer 'anti-ischemic' drugs."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs